Connect with us


Spectrum Pharmaceuticals appoints Nora E. Brennan as CFO



Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022.

Brennan has served on Spectrum’s Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role.

“We are thrilled to have Ms. Brennan join Spectrum’s senior leadership team as we progress our two late-stage assets toward commercialisation,” stated Tom Riga, CEO of Spectrum Pharmaceuticals.

“Nora has been a strong board member and her experience as the audit committee chair will serve her well in her new role. She is an accomplished business executive and I’m looking forward to working with her to advance our company.”

Brennan said:

“Spectrum is in the midst of transformation with an exciting future and I am looking forward to joining the management team.

“During my time on the Board, I have experienced firsthand the great potential in their clinical programs and confident in my ability to help position the company to maximise shareholder value.”

Most recently, Brennan served as Chief Financial Officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies driven by functional genomics.

Prior to Fore, she was the Chief Financial Officer of TELA Bio, Inc., where she guided the company through a successful IPO and follow-on financing.

Previously, Brennan spent 11 years as the Senior Vice President of Treasury and Investor Relations at Integra LifeSciences Holdings Corporation, where she served in numerous capacities and led Integra through a myriad of financings.

She was key to the capital markets strategy over a significant period of time and successfully integrated 18 acquisitions leading to significant revenue growth for the company.

She earned her B.A. in Economics from the University of Illinois at Urbana-Champaign and received her MBA from the University of Chicago Booth School of Business.

With Brennan’s announcement, Brittany Bradrick, who was recently appointed to the Board, will now assume the role of Chairperson of the Audit Committee.

Continue Reading


  1. Pingback: Four myths and a truth: What Big Pharma really thinks about digital health

  2. Pingback: Investing in Global Healthcare and Life Sciences | Health Tech World

  3. Pingback: Cerebral Therapeutics secures $40 Million Series C financing

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories